BioSpace News Archive

Drug Development

Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study

Inmagene Biopharmaceuticals announced topline results from a Phase 1 study of IMG-007, an anti-OX40 monoclonal antibody (mAb).

August 18, 2023
·
4 min read
BioCapital

Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

Aditxt®, Inc. is pleased to provide an important update regarding its innovation programs and strategic M&A initiatives.

August 18, 2023
·
9 min read
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

Can-Fite BioPharma Ltd today announced that it submitted a pediatric study plan to the U.S. Food and Drug Administration (FDA) for the treatment of adolescents suffering from psoriasis with Piclidenoson.

August 18, 2023
·
6 min read
Drug Development

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Akari Therapeutics, Plc today announced the establishment of a Boston Seaport area office that is the company’s U.S. headquarters

August 18, 2023
·
4 min read
Drug Development

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC

Akeso Inc. (“Akeso”, 9926. HK) announced today that the first patient has been dosed in a head-to-head phase III trial of ivonescimab, a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by Akeso.

August 18, 2023
·
5 min read
Business

Satio partners with BARDA DRIVe to develop a novel patch-based ebolavirus diagnostic

Satio is pleased to announce a contract awarded by the Biomedical Advanced Research and Development Authority ( BARDA ), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to develop a novel, single-use, rapid ebolavirus diagnostic.

August 18, 2023
·
2 min read
BioCapital

Zalgen Immunotherapeutic Confers Complete Protection Against Advanced Multilineage Lassa Infections in Nonhuman Primates

Zalgen Labs LLC today announced publication of data demonstrating that Arevirumab-3®, its lead immunotherapeutic candidate, is an effective therapeutic for the treatment of Lassa virus infections, with activity against all major viral lineages that cause severe disease in humans, and at very low dosages.

August 18, 2023
·
4 min read
Drug Development

Amber Ophthalmics Announces First Patient Enrolled in NEXPEDE-1, a Phase 2/3 Clinical Trial Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defects

Amber Ophthalmics, Inc. (Amber) , a privately held, clinical stage biopharmaceutical company, announced today that Dr. Mark S. Gorovoy from Gorovoy M.D. Eye Specialists has enrolled the first patient in the AMB-01-006 (NEXPEDE-1) study.

August 18, 2023
·
2 min read
Drug Development

Mindbio Therapeutics First Batch of MB22001 has Been Manufactured and is Ready for Use in World First Phase 2 Take at Home Psychedelic Clinical Trials

MindBio Therapeutics Corp. is excited to announce it has received its first batch of MB22001 ready for take-home use in Phase 2 psychedelic microdosing clinical trials.

August 18, 2023
·
5 min read
Clinical Trials Market Size Estimated to Hit USD 83,550 Million by 2032

The global clinical trials market size reached USD 48,680 million in 2022 and is estimated to hit around USD 83,550 million by 2032, expanding at a CAGR of 5.6% from 2023 to 2032, As per the study by Towards Healthcare.

August 18, 2023
·
10 min read